ORLANDO, Fla., May 21, 2013 (GLOBE NEWSWIRE) -- Given Imaging Ltd, (Nasdaq:GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced that numerous studies presented at Digestive Disease Week ® confirm the value of ManoScan high resolution manometry and the utility of applying the Chicago Classification System, ManoScan's proprietary standardized categorization system, to identify and classify motility disorders. Additional data were presented validating the use of ManoScan ® AR and ManoScan ® ESO 3D. All data were presented during Digestive Disease Week (DDW) taking place May 18 - 21, 2013 at the Orange County Convention Center, Orlando, FL.
"The studies presented at DDW show that by using Chicago Classification we can classify patient populations according to the severity of their motility disorders," said Sabine Roman, M.D., Ph.D., Lyon I University. "ManoScan is the only product that integrates this clinically proven categorization system, which gives us the valuable information we need to make important therapeutic management decisions for patients."
Several podium and poster presentations at DDW showed a range of clinical applications involving high resolution manometry in patients with achalasia, abnormal anorectal function, reflux and functional heartburn. Specific studies underscoring ManoScan's proprietary standardized categorization system, Chicago Classification, were also highlighted and include:
- Is the Chicago Classification for Esophageal Motility Disorders Useful to Predict Symptom Severity?, poster Sa1323: Researchers led by Sabine Roman, MD, PhD., Lyon I University, analyzed the application of the Chicago Classification system in accurately categorizing esophageal motility disorders according to symptom severity. Researchers conducted a randomized study evaluating 75 patients who had undergone high resolution manometry. Data from the study concluded that the Chicago Classification can be used to segregate esophageal motility disorders according to symptom severity. Researchers also found that patients with achalasia had more severe dysphagia than the normal subjects.
- The Chicago Classification of Esophageal Motility Disorders and Associated Self Report Symptom Severity, Psychological Distress, and Visceral Sensitivity, poster Su1898: Researchers at the Feinberg School of Medicine, Northwestern University, presented data from a retrospective study of 894 patients who underwent high resolution manometry. Patients were segmented into four subgroups according to Chicago Classification criteria: normal, borderline motor function, abnormal motor function and achalasia/esophagogastric junction (EGJ) outflow obstruction. Patients completed an Impaction Dysphagia Questionnaire (IDQ) that self-reported dysphagia severity. Data from this survey were analyzed and compared to the segmentation of patient subgroups by the Chicago Classification criteria. Researchers concluded that patients in the subgroups with abnormal motor function and achalasia/EGJ outflow obstruction had significantly higher IDQ scores when compared to patients in the other two subgroups validating that Chicago Classification accurately segmented motility disorder severity.
- Patients Over the Age of 40, Diagnosed With Type 1 Achalasia by Chicago Classification, Show the Best Indication for Pneumatic Dilatation, poster Su1511: Researchers at Nippon Medical School, Tokyo, Japan and Inzai, Japan, assessed the impact of the Chicago Classification System on determining the outcomes of pneumatic dilatation (PD), a procedure that aims to enlarge the esophageal lumen, in patients with achalasia. Over a period of more than nine and a half years, 73 patients were diagnosed with achalasia using high resolution manometry. Patients were categorized using Chicago Classification into three subtypes ranging from least severe, Type 1 achalasia, to most severe, Type 3 achalasia. Researchers found that patients categorized with Type 1 achalasia had the best response to PD compared with Type 2 and Type 3 subcategories of patients. Furthermore, the response rate to PD in patients with Type 1 was significantly greater than in patients with Type 2. Researchers also found that age is a useful indicator to predict PD outcomes and concluded patients over 40 years of age with Type 1 achalasia show the best indication for PD.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV